LeaFix developed a Transcatheter Mitral valve repair solution performed by an augmentation of the anterior leaflet.

​

​

​

​

​

​

​

​

​

​

​

​

​​

Company Development Stage

​

The company is soon to start First In Human (FIH) Trial after extremely promising results in animal trials.

​

Technology Main Advantages

​

• Preserved Physiology: Augments the anterior leaflet to achieve robust coaptation while maintaining a single physiologic orifice and native valve anatomy. This also minimizes the risk of stenosis or LVOT obstruction.

• 21 Fr Transseptal Delivery System: Deployed via a minimally invasive, transfemoral-transseptal approach.

• No Permanent Anticoagulation: Intentionally engineered to eliminate long-term pharmaceutical burdens for the patient.

• Universal Design & Freedom of Choice: Features a single, universal device size appropriate for all patients, lowering hospital inventory costs. Additionally, it preserves future clinical pathways by leaving TEER or TMVR wide open as viable bail-out options if needed.

• Transcatheter (TEER or TMVR) bailout